ACET
Price
$0.67
Change
+$0.01 (+1.52%)
Updated
Jun 26, 04:59 PM (EDT)
Capitalization
55.47M
41 days until earnings call
RGNX
Price
$8.75
Change
+$0.21 (+2.46%)
Updated
Jun 26, 04:59 PM (EDT)
Capitalization
430.32M
34 days until earnings call
Interact to see
Advertisement

ACET vs RGNX

Header iconACET vs RGNX Comparison
Open Charts ACET vs RGNXBanner chart's image
Adicet Bio
Price$0.67
Change+$0.01 (+1.52%)
Volume$5.75K
Capitalization55.47M
REGENXBIO
Price$8.75
Change+$0.21 (+2.46%)
Volume$32.48K
Capitalization430.32M
ACET vs RGNX Comparison Chart in %
Loading...
ACET
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACET vs. RGNX commentary
Jun 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACET is a Buy and RGNX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 27, 2025
Stock price -- (ACET: $0.66 vs. RGNX: $8.54)
Brand notoriety: ACET and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACET: 69% vs. RGNX: 54%
Market capitalization -- ACET: $55.47M vs. RGNX: $430.32M
ACET [@Biotechnology] is valued at $55.47M. RGNX’s [@Biotechnology] market capitalization is $430.32M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.01B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACET’s FA Score shows that 2 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • ACET’s FA Score: 2 green, 3 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, ACET is a better buy in the long-term than RGNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACET’s TA Score shows that 5 TA indicator(s) are bullish while RGNX’s TA Score has 4 bullish TA indicator(s).

  • ACET’s TA Score: 5 bullish, 4 bearish.
  • RGNX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ACET is a better buy in the short-term than RGNX.

Price Growth

ACET (@Biotechnology) experienced а -1.64% price change this week, while RGNX (@Biotechnology) price change was -0.35% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.00%. For the same industry, the average monthly price growth was +32.55%, and the average quarterly price growth was +15.13%.

Reported Earning Dates

ACET is expected to report earnings on Aug 06, 2025.

RGNX is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+2.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGNX($430M) has a higher market cap than ACET($55.5M). RGNX YTD gains are higher at: 10.479 vs. ACET (-31.601). ACET has higher annual earnings (EBITDA): -110.82M vs. RGNX (-122.44M). RGNX has more cash in the bank: 268M vs. ACET (150M). ACET has less debt than RGNX: ACET (16.2M) vs RGNX (79.8M). RGNX has higher revenues than ACET: RGNX (157M) vs ACET (0).
ACETRGNXACET / RGNX
Capitalization55.5M430M13%
EBITDA-110.82M-122.44M91%
Gain YTD-31.60110.479-302%
P/E RatioN/AN/A-
Revenue0157M-
Total Cash150M268M56%
Total Debt16.2M79.8M20%
FUNDAMENTALS RATINGS
ACET vs RGNX: Fundamental Ratings
ACET
RGNX
OUTLOOK RATING
1..100
6554
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
73
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
8862
P/E GROWTH RATING
1..100
1721
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACET's Valuation (32) in the Medical Distributors industry is somewhat better than the same rating for RGNX (73) in the Biotechnology industry. This means that ACET’s stock grew somewhat faster than RGNX’s over the last 12 months.

ACET's Profit vs Risk Rating (100) in the Medical Distributors industry is in the same range as RGNX (100) in the Biotechnology industry. This means that ACET’s stock grew similarly to RGNX’s over the last 12 months.

ACET's SMR Rating (97) in the Medical Distributors industry is in the same range as RGNX (97) in the Biotechnology industry. This means that ACET’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's Price Growth Rating (62) in the Biotechnology industry is in the same range as ACET (88) in the Medical Distributors industry. This means that RGNX’s stock grew similarly to ACET’s over the last 12 months.

ACET's P/E Growth Rating (17) in the Medical Distributors industry is in the same range as RGNX (21) in the Biotechnology industry. This means that ACET’s stock grew similarly to RGNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACETRGNX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 16 days ago
75%
Declines
ODDS (%)
Bearish Trend 9 days ago
87%
Bearish Trend 4 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
64%
View a ticker or compare two or three
Interact to see
Advertisement
ACET
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ERBIX19.07N/A
N/A
Eaton Vance RBA Equity Strategy Fd Cl I
JNBCX10.09N/A
N/A
JPMorgan Income Builder C
AXVIX17.28N/A
N/A
Acclivity Small Cap Value I
FAVAX23.99N/A
N/A
Fidelity Advisor Equity Value A
OILVX19.37-0.10
-0.51%
Optimum Large Cap Value Instl

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with DNLI. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
-0.23%
DNLI - RGNX
55%
Loosely correlated
+0.35%
ARWR - RGNX
53%
Loosely correlated
-1.88%
BEAM - RGNX
53%
Loosely correlated
-2.27%
VYGR - RGNX
51%
Loosely correlated
-2.00%
XNCR - RGNX
50%
Loosely correlated
+3.51%
More